Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Akshay Kharat"'
Autor:
Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Lee Smolen, Xueting Yu, Adam D. Cohen
Publikováno v:
Oncology and Therapy, Vol 11, Iss 2, Pp 263-275 (2023)
Abstract Introduction Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relaps
Externí odkaz:
https://doaj.org/article/ac25c55cc6c14ce2a868c9a66e746631
Autor:
Mark Alberts, Maryia Zhdanava, Dominic Pilon, Gabrielle Caron-Lapointe, Patrick Lefebvre, Brahim Bookhart, Akshay Kharat
Publikováno v:
Advances in Therapy. 40:2339-2354
Autor:
Mark Alberts, Maryia Zhdanava, Dominic Pilon, Gabrielle Caron-Lapointe, Patrick Lefebvre, Brahim Bookhart, Akshay Kharat
Publikováno v:
Advances in Therapy. 40:1750-1764
Publikováno v:
Blood Coagulation & Fibrinolysis. 33:301-309
This study was conducted in patients treated for initial venous thromboembolism (VTE) for approximately 6 months to enhance understanding of the risk factors to inform clinical decision-making about long-term anticoagulation therapy. This retrospecti
Autor:
Jeffrey S. Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre, Veronica Ashton
Publikováno v:
Journal of Thrombosis and Thrombolysis. 54:438-448
Prior observational studies suggest rivaroxaban is safe and effective among patients with morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are more limited in the broader population of VTE patients with obesity. Thi
Autor:
François Laliberté, Connie N. Hess, Marc P. Bonaca, John Benson, Peter Zuckerman, Dejan Milentijevic, Urvi Desai, Akshay Kharat, William R. Hiatt, Patrick Lefebvre
Publikováno v:
Annals of Vascular Surgery. 75:217-226
Background Patients with peripheral artery disease (PAD) treated with lower extremity revascularization are at increased risk of major atherothrombotic vascular events (acute limb ischemia (ALI), major non-traumatic lower-limb amputation, myocardial
Autor:
Patrick Lefebvre, John Benson, Marc P. Bonaca, Connie N. Hess, William R. Hiatt, Urvi Desai, Peter Zuckerman, Akshay Kharat, Dejan Milentijevic, François Laliberté
Publikováno v:
Journal of Medical Economics. 24:402-409
Peripheral artery disease (PAD), often treated with lower extremity revascularization, is associated with risk of major atherothrombotic vascular events (acute limb ischemia [ALI], major non-traumatic lower-limb amputation, myocardial infarction [MI]
Publikováno v:
International Journal of Orthopaedics Sciences. 6:900-903
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(4)
Current evidence suggests that rivaroxaban may be well tolerated and effective in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited evidence on the impact of polypharmacy in this population. This study evalua
Publikováno v:
Current medical research and opinion. 38(1)
OBJECTIVE To perform a systematic literature review and indirect treatment comparison (ITC) to identify, summarize and quantify randomized controlled trial (RCT) evidence evaluating combination anticoagulant or P2Y12 inhibitor with low-dose aspirin v